2022 American Transplant Congress
Evaluation of Compliance and Efficacy with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Tacrolimus in Kidney Transplant Recipients
*Purpose: The purpose of this study is to evaluate compliance and efficacy of The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype guided tacrolimus…2022 American Transplant Congress
Engineered IL-2 Plus Calcineurin Inhibitor Synergistically Expands Regulatory T Cells Transduced with Engineered IL-2 Receptor and Facilitates Establishment of Transplantation Tolerance
*Purpose: Clinical trials for regulatory T cell (Treg) therapy in organ transplant has shown promising results. However, it is still under the debate which drugs…2022 American Transplant Congress
Differences of Fk-Binding Protein 12 and P-Glycoprotein Explain the Differences in the Intracellular Tacrolimus Concentration of T Lymphocytes and Monocytes
Erasmus MC, Rotterdam, Netherlands
*Purpose: Little is known about the pharmacokinetics of intracellular tacrolimus, particularly in T lymphocytes and monocytes. We demonstrated a significantly lower intracellular tacrolimus concentration in…2022 American Transplant Congress
NecroX-7 Ameliorate FK506-Induced Nephrotoxicity in LLC-PK1 Cells (Pig Kidney Epithelial Cells)
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…2022 American Transplant Congress
The Impact of Long-Term Exposure to Tacrolimus on Chronic Kidney Disease Following Lung Transplantation: A Retrospective Analysis from a Single Transplantation Center
*Purpose: Chronic kidney disease (CKD) is a progressive and irreversible complication in lung transplant patients who have received long-term treatment with tacrolimus. This study aimed…2022 American Transplant Congress
Influence of Converting Kidney Transplant Recipients with High Tacrolimus Variability to the Once Daily LCP Tac Formulation
Med Univ of South Carolina, Charleston, SC
*Purpose: Tacrolimus (Tac) is the cornerstone of immunosuppression used in kidney transplant recipients (KTRs). Tac high variability, low time in therapeutic range and non-adherence are…2022 American Transplant Congress
The Impact of Tacrolimus Trough Variability on Acute Rejection Following Lung Transplantation
*Purpose: This study aimed to evaluate the association of tacrolimus coefficient of variation (CV) with biopsy-proven acute cellular rejection in the first year following lung…2021 American Transplant Congress
Safety and Tolerability of Tacrolimus Extended-Release (astagraf Xl) in Hla Sensitized Kidney Transplant Recipients: A Single Center Experience
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Pill burden is a limitation in kidney transplant. Tacrolimus extended-release (Astagraf XL) is a once daily formulation approved for kidney transplantation. Increased compliance could…2021 American Transplant Congress
Modeling of Alternative Weight-Based Dosing Strategies of LCP-Tacrolimus in De Novo Kidney Transplant Patients
*Purpose: LCP-tacrolimus (LCPT; Envarsus XR®) is a modified-release once-daily formulation approved for prophylaxis of organ rejection in de novo kidney transplant patients in combination with…2021 American Transplant Congress
Tacrolimus Dose Requirements in Lung Transplant Recipients on Systemic Azole Antifungals: The Influence of Race and Transplant Indication
*Purpose: CYP3A5 polymorphisms, drug interactions, and alterations in gastric absorption impact tacrolimus metabolism. This is important for those at higher risk of expressing these factors,…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »